-
Posted by
Two Blokes Jun 21 -
Filed in
Stock
-
3 views
Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year.